Diffuse Scleroderma clinical trials at UCSF
2 in progress, 1 open to eligible people
Showing trials for
Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
open to eligible people ages 18-65
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
San Francisco, California and other locations
BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Sorry, not currently recruiting here
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
San Francisco, California and other locations
Last updated: